stockrow
Saturday 7 November 2026
Export AZTR’s income statement to Excel — free account
Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.
- EPS
- +85.3%
- Free cash flow
- −19.6%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow AZTR
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (256.67%) | (158.71%) | (230.65%) | (215.04%) |
+8 more TTM periods Free account |
|
| (190.69%) | (131.02%) | (176.92%) | (157.91%) | ||
ROIC |
(1,272.49%) | (1,717.97%) | (395.49%) | (796.07%) | |
Return on Tangible Assets |
(190.29%) | (121.29%) | (438.23%) | (1,107.39%) | |
Average Days of Receivables |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(5.90) | (6.98) | (23.40) | (27.03) | |
Free Cash Flow |
(11.39) | (10.83) | (11.41) | (11.13) | |
Capital Expenditures |
(0.28) | (0.20) | (0.18) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(80.96%) | (52.74%) | (194.35%) | (302.42%) | |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(1,154.04) | (1,204.12) | (1,424.25) | (1,432.60) | |
Operating CF/Net income |
0.90 | 0.90 | 1.02 | 0.98 | |
Depreciation/Fixed assets |
2.01 | 2.03 | 0.83 | 0.79 | |
Capex/Depreciation |
(0.26) | (0.18) | (0.40) | (0.47) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.75) | (6.85) | (23.03) | (26.51) | |
Capex per Share |
(0.14) | (0.13) | (0.38) | (0.52) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026